• Catherine Lassale, Claire Sibenaler, Jehan-Michel Béhier, Philippe Barthélémy, Yannick Plétan, and Soizic Courcier.
• Les entreprises du médicament (Leem), Paris, France.
• Therapie. 2013 Jan 1; 68 (1): 1-18.

AbstractSince 2002, the Leem (French Association of Pharmaceutical Companies) has conducted a survey every two years to update the attractiveness of France for international clinical trials. Thirty companies (68% of the French market) have participated in this 6(th) survey which involved 79 countries, a greater number of Phases I/II, II and III studies (420 versus 352 in 2010), a relatively stable number of included patients (246,895 versus 249,704 in 2010) and a greater number of centers (32,965 versus 24,337 in 2010). The evolution of time-lines for the go-ahead by French Authorities is heterogeneous (shorter time-lines by the French National Agency of Drug and Health Products Safety [ANSM] but longer time-lines by Research Ethics Comittees [CPP]). The time-lines for first hospital contracts remain stable. France ranks at an average position among European countries in regards to quantitative and qualitative data, and its state-of-art in early stages is still recognized. Its good performance in oncology and orphan diseases are major assets of competitiveness.© 2013 Société Française de Pharmacologie et de Thérapeutique.

17 keywords...

hide…